// App-Quantinova.ai

2522 : A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.

Researchers

Presenter

  • Kyriakos P. Papadopoulos

Principal Investigators

  • Anthony W. Tolcher

  • Lainie P. Martin

  • Lieve Adriaens

  • Carrie M. Brownstein

  • Israel Lowy

  • Bo Gao

  • Ana Kostic

  • A Thomas DiCioccio

  • Pamela Trail

  • Philippe L. Bedard

  • Drew Warren Rasco

  • Alex Amaya

  • Kathleen N. Moore

  • Jason A. Konner

  • Daniela Matei

  • Lillian L. Siu

  • Albiruni R. A. Razak

  • Amita Patnaik

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • START Center for Cancer Care, San Antonio, TXMemorial Sloan-Kettering Cancer Center, New York, NYPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • South Texas Accelerated Research Therapeutics (START) Center for Cancer Care, San Antonio, TX

  • Indiana University School of Medicine Department of Pathology, Indianapolis, IN

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ziv-aflibercept

  • Aflibercept

  • Nesvacumab

Outcome

  • Indeterminate

Study Design

  • pharmacodynamics

Phase

  • I

Study Id's

  • NCT01688960

Sponsors

  • Regeneron Pharmaceuticals

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved